title: Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome.
abstract: OBJECTIVE
  To determine the prevalence and characteristics of coronary heart disease (CHD) risk factors in patients with chronic schizophrenia or schizoaffective disorder.
  
  
  METHODS
  We compared individual CHD risk factors and Framingham risk predictions in a group of 240 patients with a large national sample (Canadian Heart Health Survey) matched for age and sex. In addition, we compared rates of the metabolic syndrome (syndrome X) with recently published rates in the US adult population.
  
  
  RESULTS
  Compared with the reference population, Framingham 10-year risk of myocardial infarction was greater in the male patients (t3091 = 4.35, P < 0.001) but not in the female patients. Prevalence rates of the metabolic syndrome in the patients (42.6% of men and 48.5% of women) were approximately 2 times published rates in the US adult population. Further, the syndrome appears to occur at a younger age than in the general population.
  
  
  CONCLUSIONS
  These long-term patients have increased CHD risks best captured by the metabolic syndrome conceptualization coupled with a high rate of cigarette smoking. This characterization is consistent with increased cardiovascular morbidity and decreased life expectancy in both men and women. We underscore the importance of both screening for and treating potentially reversible CHD risk factors in schizophrenia patients.
authors.affiliation: Department of Psychiatry, University of Toronto, and Center for Addiction and Mental Health, Toronto, Ontario. Tony_Cohn@CAMH.net
authors.forename: Tony
authors.initials: T
authors.lastname: Cohn
authors.forename: Denis
authors.initials: D
authors.lastname: Prud'homme
authors.forename: David
authors.initials: D
authors.lastname: Streiner
authors.forename: Homa
authors.initials: H
authors.lastname: Kameh
authors.forename: Gary
authors.initials: G
authors.lastname: Remington
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000453:epidemiology / Q000209:etiology; D008017:Life Expectancy; D008297:Male; D024821:Metabolic Syndrome / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology; D008875:Middle Aged; D015995:Prevalence; D012307:Risk Factors; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D012720:Severity of Illness Index; D012907:Smoking / Q000453:epidemiology; D014280:Triglycerides / Q000097:blood
chemical_list: D014150:Antipsychotic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides